ReviewFrontiers in oncology2026
Hemozoin-induced immunomodulation and prostate carcinogenesis: mechanisms and implications.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemozoin (Hz) is a crystalline by-product, which is produced when the Plasmodium species destroy haemoglobin, and it is commonly recognised that it leads to how our bodies respond to malaria. Although we understand pretty well its immunological actions in infectious diseases, recent research indicates that chronic exposure to Hz may actually cause cancer by sustaining inflammation and altering the immune system. In this review, we examines how the relationship between the hemozoin induced immune changes contribute to prostate cancer development arises. The presence of Hz within the macrophages and dendritic cells can modulate inflammatory signalling pathways, including NF-kB, MAPK, and STAT3, particularly in the context of co-stimulation with parasite or host-derived ligands, thereby sustaining low-grade inflammation over time. These processes can result in amplified cell growth, inhibition of cell death, and genomic instability, which are typical of cancer. In addition, while several in vitro studies have reported that the purified hemozoin elicits weak or no cytokines, it has accumulated Hz amplify responses to infections or Toll-like receptor ligands, consistent with a primarily agonistic role. Hz is seen to direct macrophages to a tumour-promoting M2, suppress cytotoxic T-cells, and increase the performance of regulatory T cells, all of which are detrimental to the immune response against tumours. The connections between Toll-like receptor (TLR) signalling, oxidative stress, and PI3K/Akt/mTOR are also investigated in relation to the possibility of encouraging tumour development in prostate conditions. Epidemiologically, malaria endemic regions also report an increase in prostate cancer incidence, though this ecological overlap is subject to major cofounding, it raises the hypothesis that repeated exposure to malaria and subsequently Hz might contribute to prostate cancer, which necessitates further studies. In addition, improved malaria control, demographic ageing, coinfections, and other factors are likely to obscure any direct association. A better comprehension of these relationships may present the possibility of novel diagnostic measures and specific interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.